Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
09:46am, Tuesday, 18'th May 2021
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
Why BioCryst Pharmaceuticals Stock Is Jumping Today
01:10pm, Monday, 17'th May 2021
Investors appear to be increasingly optimistic about the outlook for its drug Orladeyo.
RESEARCH TRIANGLE PARK, N.C., May 12, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the United Kingdom's Medicines and Healthcare products Regulatory Agen
Strength Seen in BioCryst (BCRX): Can Its 21% Jump Turn into More Strength?
03:01am, Friday, 07'th May 2021
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst: Solid Delivery And Follow Through
03:34pm, Thursday, 06'th May 2021
BioCryst has two approved products.
BCRX Stock: 24.35% Increase (From $10.68 To $13.28) Intraday Explanation
02:45pm, Thursday, 06'th May 2021
The stock price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) increased by 24.35% (from $10.68 to $13.28) during intraday trading today. This is why it happened.
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2021 Results - Earnings Call Transcript
02:26pm, Thursday, 06'th May 2021
BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse on Q1 2021 Results - Earnings Call Transcript
BioCryst Shares Trading Higher As Q1 Sales Beat Was Supported By Orladeyo Revenues
12:32pm, Thursday, 06'th May 2021
BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) reported a first-quarter loss of $0.36, wider than the consensus loss of $0.27 and deeper than the EPS loss of $0.24 reported a year ago mainly driven by
Why BioCryst Pharmaceuticals Stock Is Soaring Today
11:06am, Thursday, 06'th May 2021
The drugmaker reported better-than-expected Q1 results.
RESEARCH TRIANGLE PARK, N.C., April 30, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the European Commission (EC) has approved oral, once-daily ORLADEYO�
BioCryst Announces Approval of Japanese NHI Price Listing of ORLADEYO™ (berotralstat) for Prophylactic Treatment of Hereditary Angioedema
08:15am, Wednesday, 14'th Apr 2021
—ORLADEYO is the first and only approved prophylactic therapy for HAE in Japan—
BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference
07:00am, Wednesday, 07'th Apr 2021
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcar
BCRX Stock Price: $15 Target By Piper Sandler
08:24am, Saturday, 27'th Mar 2021
The stock price of BioCryst Pharmaceuticals (NASDAQ: BCRX) has received a price target of $15 by Piper Sandler. These are the details.
BioCryst Technical Levels To Watch
01:27pm, Monday, 22'nd Mar 2021
BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) announced results from a dose-ranging trial evaluating BCX9930 in treatment-naïve paroxysmal nocturnal hemoglobinuria (PNH) patients and PNH patients with
FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings
09:52am, Saturday, 20'th Mar 2021
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the bigges
